Skip to main content

Table 1 Correlation between clinicopathological characteristics and NMF typing in the TCGA database

From: Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing

Characteristics

C1 (N = 185)

C2 (N = 316)

Total (N = 501)

P-value

Age

 Mean ± standard deviation

66.33 ± 8.74

67.71 ± 8.46

67.20 ± 8.58

0.0836

 Median [min, max]

68 [39, 85]

68 [40, 90]

68 [39, 90]

 

Gender

 Female

36 (7.19%)

94 (18.76%)

130 (25.95%)

0.0112*

 Male

149 (29.74%)

222 (44.31%)

371 (74.05%)

T

 T1

36 (7.19%)

78 (15.57%)

114 (22.75%)

0.5468

 T2

112 (22.36%)

181 (36.13%)

293 (58.48%)

 T3

29 (5.79%)

42 (8.38%)

71 (14.17%)

 T4

8 (1.60%)

15 (2.99%)

23 (4.59%)

N

 N0

112 (22.36%)

207 (41.32%)

319 (63.67%)

0.1161

 N1

57 (11.38%)

74 (14.77%)

131 (26.15%)

 N2

16 (3.19%)

24 (4.79%)

40 (7.98%)

 N3

0

5 (1.00%)

5 (1.00%)

 Nx

0

6 (1.20%)

6 (1.20%)

 

M

 M0

149 (29.74%)

262 (52.30%)

411 (82.04%)

0.4213

 M1

1 (0.20%)

6 (1.20%)

7 (1.40%)

 Mx

34 (6.79%)

45 (8.97%)

79 (15.76%)

 

 Unknown

1 (0.20%)

3 (0.60%)

4 (0.80%)

 

Stage

 Stage I

80 (15.97%)

164 (32.73%)

244 (48.70%)

0.1160

 Stage II

68 (13.57%)

94 (18.76%)

162 (32.34%)

 Stage III

35 (6.99%)

49 (9.78%)

84 (16.77%)

 Stage IV

1 (0.20%)

6 (1.20%)

7 (1.40%)

 Unknown

1 (0.20%)

3 (0.60%)

4 (0.80%)

 

IPTS groups

 High score

52 (10.38%)

254 (50.70%)

306 (61.08%)

< 0.0001****

 Low score

133 (26.55%)

62 (12.38%)

195 (38.92%)

  1. Bold values indicate P < 0.05 and *P < 0.05, ****P < 0.0001